25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NYKD (Nykode) Stock Analysis
Buy, Hold or Sell?

Let's analyze Nykode together

I guess you are interested in Nykode Therapeutics ASA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Nykode’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Nykode’s Price Targets

I'm going to help you getting a better view of Nykode Therapeutics ASA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Nykode Therapeutics ASA

I send you an email if I find something interesting about Nykode Therapeutics ASA.

1. Quick Overview

1.1. Quick analysis of Nykode (30 sec.)










1.2. What can you expect buying and holding a share of Nykode? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr4.15
Expected worth in 1 year
kr3.38
How sure are you?
21.1%

+ What do you gain per year?

Total Gains per Share
kr-0.77
Return On Investment
-42.8%

For what price can you sell your share?

Current Price per Share
kr1.79
Expected price per share
kr1.5678 - kr1.978
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Nykode (5 min.)




Live pricePrice per Share (EOD)
kr1.79
Intrinsic Value Per Share
kr-43.45 - kr-51.47
Total Value Per Share
kr-39.30 - kr-47.32

2.2. Growth of Nykode (5 min.)




Is Nykode growing?

Current yearPrevious yearGrowGrow %
How rich?$133.9m$149.9m-$8.7m-6.2%

How much money is Nykode making?

Current yearPrevious yearGrowGrow %
Making money-$6.3m-$9.9m$3.6m56.9%
Net Profit Margin-818.4%-651.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Nykode (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#298 / 872

Most Revenue
#412 / 872

Most Profit
#454 / 872

Most Efficient
#684 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Nykode?

Welcome investor! Nykode's management wants to use your money to grow the business. In return you get a share of Nykode.

First you should know what it really means to hold a share of Nykode. And how you can make/lose money.

Speculation

The Price per Share of Nykode is kr1.794. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nykode.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nykode, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr4.15. Based on the TTM, the Book Value Change Per Share is kr-0.19 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nykode.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-0.2%-0.02-1.1%-0.03-1.7%-0.03-1.6%0.000.3%0.000.3%
Usd Book Value Change Per Share-0.01-0.4%-0.02-1.1%0.010.4%-0.01-0.8%0.021.2%0.021.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.4%-0.02-1.1%0.010.4%-0.01-0.8%0.021.2%0.021.2%
Usd Price Per Share0.22-0.62-2.13-1.76-3.29-3.29-
Price to Earnings Ratio-12.19--9.08--20.51--16.24--23.62--23.62-
Price-to-Total Gains Ratio-31.06--34.08--50.46--56.97--119.28--119.28-
Price to Book Ratio0.53-1.38-4.75-3.72-6.39-6.39-
Price-to-Total Gains Ratio-31.06--34.08--50.46--56.97--119.28--119.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1772472
Number of shares5641
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.02
Usd Total Gains Per Share-0.020.02
Gains per Quarter (5641 shares)-106.96121.76
Gains per Year (5641 shares)-427.85487.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-428-4380487477
20-856-8660974964
30-1284-1294014611451
40-1711-1722019481938
50-2139-2150024352425
60-2567-2578029222912
70-2995-3006034093399
80-3423-3434038963886
90-3851-3862043834373
100-4279-4290048704860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.017.00.010.5%2.017.00.010.5%2.017.00.010.5%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.015.00.021.1%4.015.00.021.1%4.015.00.021.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.015.00.021.1%4.015.00.021.1%4.015.00.021.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Nykode Therapeutics ASA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.070-0.192+173%0.081-187%-0.141+101%0.218-132%0.218-132%
Book Value Per Share--4.1514.376-5%4.648-11%4.696-12%4.731-12%4.731-12%
Current Ratio--16.92511.757+44%7.562+124%8.602+97%10.576+60%10.576+60%
Debt To Asset Ratio--0.0860.127-32%0.216-60%0.204-58%0.208-59%0.208-59%
Debt To Equity Ratio--0.0950.146-35%0.279-66%0.265-64%0.270-65%0.270-65%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--584344434.4081838312747.166-68%7070165729.090-92%6239974882.112-91%12310200275.435-95%12310200275.435-95%
Eps---0.045-0.196+338%-0.308+588%-0.284+535%0.050-190%0.050-190%
Free Cash Flow Per Share---0.322-0.370+15%-0.711+121%-0.498+55%-0.329+2%-0.329+2%
Free Cash Flow To Equity Per Share---0.322-0.370+15%-0.713+121%-0.499+55%-0.294-9%-0.294-9%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---51.474----------
Intrinsic Value_10Y_min---43.448----------
Intrinsic Value_1Y_max---2.454----------
Intrinsic Value_1Y_min---2.409----------
Intrinsic Value_3Y_max---9.434----------
Intrinsic Value_3Y_min---8.965----------
Intrinsic Value_5Y_max---18.899----------
Intrinsic Value_5Y_min---17.364----------
Market Cap585823495.296-22%712524340.8082049568755.766-65%7044417424.690-90%5806425347.512-88%10887663314.117-93%10887663314.117-93%
Net Profit Margin----8.1840%-6.5150%-7.7030%-6.8320%-6.8320%
Operating Margin----0%-0.5970%-3.4780%-4.3830%-4.3830%
Operating Ratio---13.360-100%9.567-100%11.721-100%9.883-100%9.883-100%
Pb Ratio0.432-22%0.5261.382-62%4.750-89%3.724-86%6.392-92%6.392-92%
Pe Ratio-10.023+18%-12.191-9.082-26%-20.512+68%-16.244+33%-23.625+94%-23.625+94%
Price Per Share1.794-22%2.1826.277-65%21.573-90%17.781-88%33.342-93%33.342-93%
Price To Free Cash Flow Ratio-1.393+18%-1.694-4.034+138%-9.646+469%-10.328+510%-24.364+1338%-24.364+1338%
Price To Total Gains Ratio-25.537+18%-31.060-34.083+10%-50.460+62%-56.968+83%-119.283+284%-119.283+284%
Quick Ratio---0.001-100%1.718-100%2.741-100%7.272-100%7.272-100%
Return On Assets---0.010-0.038+288%-0.053+436%-0.048+383%-0.023+131%-0.023+131%
Return On Equity---0.011-0.044+311%-0.067+526%-0.061+466%-0.026+144%-0.026+144%
Total Gains Per Share---0.070-0.192+173%0.081-187%-0.141+101%0.218-132%0.218-132%
Usd Book Value--133917124.461141188002.403-5%149961545.115-11%151493619.992-12%152650163.154-12%152650163.154-12%
Usd Book Value Change Per Share---0.007-0.019+173%0.008-187%-0.014+101%0.022-132%0.022-132%
Usd Book Value Per Share--0.4100.432-5%0.459-11%0.464-12%0.467-12%0.467-12%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--57733230.120181625299.420-68%698532374.034-92%616509518.353-91%1216247787.213-95%1216247787.213-95%
Usd Eps---0.004-0.019+338%-0.030+588%-0.028+535%0.005-190%0.005-190%
Usd Free Cash Flow---10389682.168-11928338.910+15%-22942131.845+121%-16070998.058+55%-10621156.844+2%-10621156.844+2%
Usd Free Cash Flow Per Share---0.032-0.037+15%-0.070+121%-0.049+55%-0.033+2%-0.033+2%
Usd Free Cash Flow To Equity Per Share---0.032-0.037+15%-0.070+121%-0.049+55%-0.029-9%-0.029-9%
Usd Market Cap57879361.335-22%70397404.872202497393.070-65%695988441.559-90%573674824.334-88%1075701135.435-93%1075701135.435-93%
Usd Price Per Share0.177-22%0.2160.620-65%2.131-90%1.757-88%3.294-93%3.294-93%
Usd Profit---1443677.930-6328588.157+338%-9932034.265+588%-9269931.973+542%259573.671-656%259573.671-656%
Usd Revenue---1962812.117-100%2693899.019-100%2350225.689-100%14806591.538-100%14806591.538-100%
Usd Total Gains Per Share---0.007-0.019+173%0.008-187%-0.014+101%0.022-132%0.022-132%
 EOD+3 -5MRQTTM+22 -11YOY+17 -163Y+21 -125Y+12 -2110Y+12 -21

3.3 Fundamental Score

Let's check the fundamental score of Nykode Therapeutics ASA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.023
Price to Book Ratio (EOD)Between0-10.432
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than116.925
Debt to Asset Ratio (MRQ)Less than10.086
Debt to Equity Ratio (MRQ)Less than10.095
Return on Equity (MRQ)Greater than0.15-0.011
Return on Assets (MRQ)Greater than0.05-0.010
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Nykode Therapeutics ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.643
Ma 20Greater thanMa 501.819
Ma 50Greater thanMa 1001.784
Ma 100Greater thanMa 2001.639
OpenGreater thanClose1.760
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Nykode Therapeutics ASA

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Fundamental data was last updated by Penke on 2025-06-28 10:05:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Nykode earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compareΒ Nykode to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ kr0.00 for each kr1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nykode Therapeutics ASA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-818.4%+818.4%
TTM-818.4%YOY-651.5%-166.9%
TTM-818.4%5Y-683.2%-135.1%
5Y-683.2%10Y-683.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM-818.4%-140.3%-678.1%
YOY-651.5%-196.4%-455.1%
3Y-770.3%-247.9%-522.4%
5Y-683.2%-343.3%-339.9%
10Y-683.2%-488.1%-195.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Nykode is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Nykode to theΒ Biotechnology industry mean.
  • -1.0% Return on Assets means thatΒ Nykode generatedΒ kr-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nykode Therapeutics ASA:

  • The MRQ is -1.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.0%TTM-3.8%+2.8%
TTM-3.8%YOY-5.3%+1.5%
TTM-3.8%5Y-2.3%-1.5%
5Y-2.3%10Y-2.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.0%-11.5%+10.5%
TTM-3.8%-11.5%+7.7%
YOY-5.3%-11.4%+6.1%
3Y-4.8%-11.7%+6.9%
5Y-2.3%-11.9%+9.6%
10Y-2.3%-13.7%+11.4%
4.3.1.3. Return on Equity

Shows how efficient Nykode is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Nykode to theΒ Biotechnology industry mean.
  • -1.1% Return on Equity means Nykode generated kr-0.01Β for eachΒ kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nykode Therapeutics ASA:

  • The MRQ is -1.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.1%TTM-4.4%+3.4%
TTM-4.4%YOY-6.7%+2.3%
TTM-4.4%5Y-2.6%-1.8%
5Y-2.6%10Y-2.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.1%-13.6%+12.5%
TTM-4.4%-14.8%+10.4%
YOY-6.7%-14.4%+7.7%
3Y-6.1%-16.8%+10.7%
5Y-2.6%-17.5%+14.9%
10Y-2.6%-19.5%+16.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Nykode Therapeutics ASA.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Nykode is operatingΒ .

  • Measures how much profit Nykode makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Nykode to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated kr0.00 Β for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nykode Therapeutics ASA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-59.7%+59.7%
TTM-5Y-438.3%+438.3%
5Y-438.3%10Y-438.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--221.8%+221.8%
TTM--250.7%+250.7%
YOY-59.7%-208.5%+148.8%
3Y-347.8%-220.2%-127.6%
5Y-438.3%-342.4%-95.9%
10Y-438.3%-462.5%+24.2%
4.3.2.2. Operating Ratio

Measures how efficient Nykode is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM13.360-13.360
TTM13.360YOY9.567+3.793
TTM13.3605Y9.883+3.477
5Y9.88310Y9.8830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.097-2.097
TTM13.3602.684+10.676
YOY9.5673.076+6.491
3Y11.7213.524+8.197
5Y9.8834.724+5.159
10Y9.8836.445+3.438
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Nykode Therapeutics ASA.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Nykode is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 16.92Β means the company has kr16.92 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 16.925. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.757. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ16.925TTM11.757+5.167
TTM11.757YOY7.562+4.195
TTM11.7575Y10.576+1.181
5Y10.57610Y10.5760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.9253.638+13.287
TTM11.7573.846+7.911
YOY7.5624.140+3.422
3Y8.6024.688+3.914
5Y10.5765.722+4.854
10Y10.5766.144+4.432
4.4.3.2. Quick Ratio

Measures if Nykode is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Nykode to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off kr0.00 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.001-0.001
TTM0.001YOY1.718-1.717
TTM0.0015Y7.272-7.270
5Y7.27210Y7.2720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.826-2.826
TTM0.0013.116-3.115
YOY1.7183.786-2.068
3Y2.7414.311-1.570
5Y7.2725.702+1.570
10Y7.2726.335+0.937
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Nykode Therapeutics ASA.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of NykodeΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Nykode to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09Β means that Nykode assets areΒ financed with 8.6% credit (debt) and the remaining percentage (100% - 8.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.086. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.127. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.086TTM0.127-0.040
TTM0.127YOY0.216-0.089
TTM0.1275Y0.208-0.082
5Y0.20810Y0.2080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0860.327-0.241
TTM0.1270.349-0.222
YOY0.2160.332-0.116
3Y0.2040.340-0.136
5Y0.2080.346-0.138
10Y0.2080.378-0.170
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Nykode is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Nykode to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 9.5% means that company has kr0.09 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.095. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.146. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.095TTM0.146-0.052
TTM0.146YOY0.279-0.133
TTM0.1465Y0.270-0.124
5Y0.27010Y0.2700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0950.383-0.288
TTM0.1460.438-0.292
YOY0.2790.414-0.135
3Y0.2650.450-0.185
5Y0.2700.457-0.187
10Y0.2700.512-0.242
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every kr1 in earnings Nykode generates.

  • Above 15 is considered overpriced butΒ always compareΒ Nykode to theΒ Biotechnology industry mean.
  • A PE ratio of -12.19 means the investor is paying kr-12.19Β for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nykode Therapeutics ASA:

  • The EOD is -10.023. Based on the earnings, the company is expensive. -2
  • The MRQ is -12.191. Based on the earnings, the company is expensive. -2
  • The TTM is -9.082. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.023MRQ-12.191+2.168
MRQ-12.191TTM-9.082-3.109
TTM-9.082YOY-20.512+11.430
TTM-9.0825Y-23.625+14.543
5Y-23.62510Y-23.6250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.023-2.399-7.624
MRQ-12.191-2.092-10.099
TTM-9.082-2.625-6.457
YOY-20.512-3.784-16.728
3Y-16.244-3.762-12.482
5Y-23.625-6.363-17.262
10Y-23.625-7.055-16.570
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nykode Therapeutics ASA:

  • The EOD is -1.393. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.694. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.034. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.393MRQ-1.694+0.301
MRQ-1.694TTM-4.034+2.340
TTM-4.034YOY-9.646+5.612
TTM-4.0345Y-24.364+20.330
5Y-24.36410Y-24.3640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.393-3.299+1.906
MRQ-1.694-2.742+1.048
TTM-4.034-3.801-0.233
YOY-9.646-4.402-5.244
3Y-10.328-5.140-5.188
5Y-24.364-8.483-15.881
10Y-24.364-9.296-15.068
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Nykode is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.53 means the investor is paying kr0.53Β for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Nykode Therapeutics ASA:

  • The EOD is 0.432. Based on the equity, the company is cheap. +2
  • The MRQ is 0.526. Based on the equity, the company is cheap. +2
  • The TTM is 1.382. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.432MRQ0.526-0.093
MRQ0.526TTM1.382-0.857
TTM1.382YOY4.750-3.368
TTM1.3825Y6.392-5.010
5Y6.39210Y6.3920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4322.113-1.681
MRQ0.5261.856-1.330
TTM1.3822.125-0.743
YOY4.7502.454+2.296
3Y3.7242.492+1.232
5Y6.3923.668+2.724
10Y6.3924.364+2.028
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets146,614
Total Liabilities12,667
Total Stockholder Equity133,947
 As reported
Total Liabilities 12,667
Total Stockholder Equity+ 133,947
Total Assets = 146,614

Assets

Total Assets146,614
Total Current Assets108,606
Long-term Assets38,008
Total Current Assets
Cash And Cash Equivalents 106,234
Total Current Assets  (as reported)108,606
Total Current Assets  (calculated)106,234
+/- 2,372
Long-term Assets
Property Plant Equipment 7,165
Long-term Assets  (as reported)38,008
Long-term Assets  (calculated)7,165
+/- 30,843

Liabilities & Shareholders' Equity

Total Current Liabilities6,417
Long-term Liabilities6,250
Total Stockholder Equity133,947
Total Current Liabilities
Accounts payable 3,381
Total Current Liabilities  (as reported)6,417
Total Current Liabilities  (calculated)3,381
+/- 3,036
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt3,278
Long-term Liabilities Other 885
Long-term Liabilities  (as reported)6,250
Long-term Liabilities  (calculated)4,163
+/- 2,087
Total Stockholder Equity
Total Stockholder Equity (as reported)133,947
Total Stockholder Equity (calculated)0
+/- 133,947
Other
Capital Stock367
Common Stock Shares Outstanding 326,546
Net Invested Capital 133,947
Net Working Capital 102,189
Property Plant and Equipment Gross 7,165



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
19,339
230,028
223,854
212,052
202,650
265,556
254,073
238,832
228,314
221,477
205,272
188,839
174,470
208,185
191,891
179,877
168,413
153,481
146,614
146,614153,481168,413179,877191,891208,185174,470188,839205,272221,477228,314238,832254,073265,556202,650212,052223,854230,02819,339
   > Total Current Assets 
19,180
229,032
222,948
211,260
201,734
255,858
244,076
228,875
218,619
211,873
195,160
177,822
163,361
165,675
151,832
140,020
128,720
117,066
108,606
108,606117,066128,720140,020151,832165,675163,361177,822195,160211,873218,619228,875244,076255,858201,734211,260222,948229,03219,180
       Cash And Cash Equivalents 
18,017
183,851
179,738
174,378
172,645
216,231
225,681
213,279
212,021
205,843
186,163
173,583
159,132
161,954
147,296
136,534
124,619
114,818
106,234
106,234114,818124,619136,534147,296161,954159,132173,583186,163205,843212,021213,279225,681216,231172,645174,378179,738183,85118,017
       Short-term Investments 
0
24,944
23,748
20,774
16,319
12,169
12,234
10,035
0
0
0
0
0
0
0
0
0
0
0
0000000000010,03512,23412,16916,31920,77423,74824,9440
       Net Receivables 
0
20,087
19,462
16,108
12,770
26,155
6,161
5,561
6,598
4,333
11
4,239
542
0
220
0
86
0
0
0086022005424,239114,3336,5985,5616,16126,15512,77016,10819,46220,0870
       Other Current Assets 
0
-1
0
0
0
0
12,234
0
0
-1
0
0
0
0
0
0
0
0
0
000000000-10012,2340000-10
   > Long-term Assets 
0
0
906
792
917
9,698
9,997
9,957
9,695
9,604
10,112
11,017
11,109
42,510
40,059
39,857
39,693
36,415
38,008
38,00836,41539,69339,85740,05942,51011,10911,01710,1129,6049,6959,9579,9979,69891779290600
       Property Plant Equipment 
116
408
323
230
374
9,165
9,453
9,469
9,214
9,526
10,036
10,901
11,037
10,517
9,928
9,284
8,719
7,744
7,165
7,1657,7448,7199,2849,92810,51711,03710,90110,0369,5269,2149,4699,4539,165374230323408116
       Intangible Assets 
33
32
32
32
32
32
32
32
32
32
29
68
0
0
0
0
0
0
0
0000000682932323232323232323233
       Long-term Assets Other 
0
0
0
0
0
0
0
0
-1
0
0
1
0
0
0
0
0
-2
0
0-200000100-100000000
> Total Liabilities 
2,501
51,178
50,242
43,552
40,475
71,501
65,432
57,750
61,203
64,459
57,012
49,136
44,172
36,926
33,171
27,799
25,774
17,267
12,667
12,66717,26725,77427,79933,17136,92644,17249,13657,01264,45961,20357,75065,43271,50140,47543,55250,24251,1782,501
   > Total Current Liabilities 
2,500
13,181
13,746
9,602
10,923
31,367
31,129
27,026
35,566
38,985
33,139
26,006
23,517
20,608
18,019
15,089
16,172
9,099
6,417
6,4179,09916,17215,08918,01920,60823,51726,00633,13938,98535,56627,02631,12931,36710,9239,60213,74613,1812,500
       Accounts payable 
0
1,612
8,984
5,564
7,037
2,746
6,985
5,394
5,274
2,313
7,293
7,046
7,001
1,327
3,993
3,417
4,798
864
3,381
3,3818644,7983,4173,9931,3277,0017,0467,2932,3135,2745,3946,9852,7467,0375,5648,9841,6120
       Other Current Liabilities 
0
1,613
47
161
495
17,975
18,062
17,778
20,109
27,944
0
17,565
0
0
0
0
0
0
0
000000017,565027,94420,10917,77818,06217,975495161471,6130
   > Long-term Liabilities 
0
0
36,496
33,950
29,552
40,134
34,303
30,724
25,637
25,473
23,873
23,130
20,655
16,318
15,152
12,710
9,602
8,168
6,250
6,2508,1689,60212,71015,15216,31820,65523,13023,87325,47325,63730,72434,30340,13429,55233,95036,49600
       Long term Debt Total 
0
8
8
7
10
5,820
5,639
4,798
4,126
4,365
4,335
4,683
0
0
0
0
0
0
0
00000004,6834,3354,3654,1264,7985,6395,820107880
       Other Liabilities 
0
37,989
36,488
33,943
29,542
34,314
28,664
25,926
21,511
21,109
0
18,447
0
0
0
0
0
0
0
000000018,447021,10921,51125,92628,66434,31429,54233,94336,48837,9890
       Deferred Long Term Liability 
0
551
0
0
0
478
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000004780005510
> Total Stockholder Equity
16,838
178,850
173,612
168,500
162,175
194,055
188,641
181,082
167,111
157,018
148,260
139,703
130,298
171,259
158,720
152,078
142,639
136,214
133,947
133,947136,214142,639152,078158,720171,259130,298139,703148,260157,018167,111181,082188,641194,055162,175168,500173,612178,85016,838
   Common Stock
316
327
328
329
330
333
334
334
334
338
339
339
0
0
0
0
0
0
0
0000000339339338334334334333330329328327316
   Retained Earnings 
-41,623
116,869
110,362
104,114
96,686
107,455
100,557
91,808
76,918
64,713
66,820
45,140
34,897
29,559
15,115
7,726
-2,005
-8,762
-10,387
-10,387-8,762-2,0057,72615,11529,55934,89745,14066,82064,71376,91891,808100,557107,45596,686104,114110,362116,869-41,623
   Capital Surplus 
58,145
60,348
60,783
61,224
61,356
81,526
82,006
82,314
82,314
83,318
84,145
84,145
0
0
0
0
0
0
0
000000084,14584,14583,31882,31482,31482,00681,52661,35661,22460,78360,34858,145
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
1,306
2,139
2,833
3,803
4,741
5,744
6,626
7,545
8,649
-3,044
10,079
0
0
0
0
0
0
0
000000010,079-3,0448,6497,5456,6265,7444,7413,8032,8332,1391,3060



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue8,679
Cost of Revenue-0
Gross Profit08,679
 
Operating Income (+$)
Gross Profit0
Operating Expense-57,012
Operating Income-48,333-57,012
 
Operating Expense (+$)
Research Development14,734
Selling General Administrative4,345
Selling And Marketing Expenses0
Operating Expense57,01219,079
 
Net Interest Income (+$)
Interest Income7,002
Interest Expense-188
Other Finance Cost-0
Net Interest Income6,814
 
Pretax Income (+$)
Operating Income-48,333
Net Interest Income6,814
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-45,513-48,333
EBIT - interestExpense = -188
-38,821
-38,633
Interest Expense188
Earnings Before Interest and Taxes (EBIT)0-45,325
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-45,513
Tax Provision--6,692
Net Income From Continuing Ops-38,821-38,821
Net Income-38,821
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-6,814
 

Technical Analysis of Nykode
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nykode. The general trend of Nykode is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nykode's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Nykode Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nykode Therapeutics ASA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.951 < 1.9768 < 1.978.

The bearish price targets are: 1.713 > 1.63 > 1.5678.

Know someone who trades $NYKD? Share this with them.πŸ‘‡

Nykode Therapeutics ASA Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nykode Therapeutics ASA. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nykode Therapeutics ASA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nykode Therapeutics ASA. The current macd is 0.01237946.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nykode price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Nykode. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Nykode price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Nykode Therapeutics ASA Daily Moving Average Convergence/Divergence (MACD) ChartNykode Therapeutics ASA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nykode Therapeutics ASA. The current adx is 27.76.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Nykode shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Nykode Therapeutics ASA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nykode Therapeutics ASA. The current sar is 1.74093105.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Nykode Therapeutics ASA Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nykode Therapeutics ASA. The current rsi is 48.64. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Nykode Therapeutics ASA Daily Relative Strength Index (RSI) ChartNykode Therapeutics ASA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nykode Therapeutics ASA. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nykode price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Nykode Therapeutics ASA Daily Stochastic Oscillator ChartNykode Therapeutics ASA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nykode Therapeutics ASA. The current cci is -56.47118947.

Nykode Therapeutics ASA Daily Commodity Channel Index (CCI) ChartNykode Therapeutics ASA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nykode Therapeutics ASA. The current cmo is -10.21014054.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Nykode Therapeutics ASA Daily Chande Momentum Oscillator (CMO) ChartNykode Therapeutics ASA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nykode Therapeutics ASA. The current willr is -74.40758294.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nykode is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Nykode Therapeutics ASA Daily Williams %R ChartNykode Therapeutics ASA Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Nykode Therapeutics ASA.

Nykode Therapeutics ASA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nykode Therapeutics ASA. The current atr is 0.09349511.

Nykode Therapeutics ASA Daily Average True Range (ATR) ChartNykode Therapeutics ASA Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nykode Therapeutics ASA. The current obv is -105,787,540.

Nykode Therapeutics ASA Daily On-Balance Volume (OBV) ChartNykode Therapeutics ASA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nykode Therapeutics ASA. The current mfi is 47.16.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Nykode Therapeutics ASA Daily Money Flow Index (MFI) ChartNykode Therapeutics ASA Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nykode Therapeutics ASA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Nykode Therapeutics ASA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nykode Therapeutics ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.643
Ma 20Greater thanMa 501.819
Ma 50Greater thanMa 1001.784
Ma 100Greater thanMa 2001.639
OpenGreater thanClose1.760
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Nykode with someone you think should read this too:
  • Are you bullish or bearish on Nykode? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nykode? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nykode Therapeutics ASA

I send you an email if I find something interesting about Nykode Therapeutics ASA.


Comments

How you think about this?

Leave a comment

Stay informed about Nykode Therapeutics ASA.

Receive notifications about Nykode Therapeutics ASA in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.